A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.